EPIPHANY TECHNOLOGY ACQ-CL A (EPHY) Fundamental Analysis & Valuation

NASDAQ:EPHY • US29429X1090

Current stock price

10.095 USD
0 (-0.05%)
At close:
10.0901 USD
0 (-0.05%)
After Hours:

This EPHY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EPHY Profitability Analysis

1.1 Basic Checks

  • In the past year EPHY was profitable.
  • In the past year EPHY has reported a negative cash flow from operations.
EPHY Yearly Net Income VS EBIT VS OCF VS FCFEPHY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 0 2M 4M 6M

1.2 Ratios

Industry RankSector Rank
ROA 2.95%
ROE 3.08%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPHY Yearly ROA, ROE, ROICEPHY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 0 0.5 1 1.5

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EPHY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPHY Yearly Profit, Operating, Gross MarginsEPHY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. EPHY Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EPHY has about the same amount of shares outstanding.
  • There is no outstanding debt for EPHY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EPHY Yearly Shares OutstandingEPHY Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 10M 20M 30M 40M 50M
EPHY Yearly Total Debt VS Total AssetsEPHY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 100M 200M 300M 400M

2.2 Solvency

  • EPHY has an Altman-Z score of 18.21. This indicates that EPHY is financially healthy and has little risk of bankruptcy at the moment.
  • EPHY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.21
ROIC/WACCN/A
WACCN/A
EPHY Yearly LT Debt VS Equity VS FCFEPHY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 100M 200M 300M

2.3 Liquidity

  • EPHY has a Current Ratio of 0.20. This is a bad value and indicates that EPHY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • A Quick Ratio of 0.20 indicates that EPHY may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.2
Quick Ratio 0.2
EPHY Yearly Current Assets VS Current LiabilitesEPHY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 200K 400K 600K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. EPHY Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. EPHY Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 43.89, EPHY can be considered very expensive at the moment.
  • The average S&P500 Price/Earnings ratio is at 26.64. EPHY is valued rather expensively when compared to this.
Industry RankSector Rank
PE 43.89
Fwd PE N/A
EPHY Price Earnings VS Forward Price EarningsEPHY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPHY Per share dataEPHY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EPHY Dividend Analysis

5.1 Amount

  • EPHY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

EPHY Fundamentals: All Metrics, Ratios and Statistics

EPIPHANY TECHNOLOGY ACQ-CL A

NASDAQ:EPHY (1/12/2023, 8:07:12 PM)

After market: 10.0901 0 (-0.05%)

10.095

0 (-0.05%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap515.98M
Revenue(TTM)N/A
Net Income(TTM)11.96M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 43.89
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)0.23
EY2.28%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS7.59
TBVpS7.59
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 2.95%
ROE 3.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.2
Quick Ratio 0.2
Altman-Z 18.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.37%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

EPIPHANY TECHNOLOGY ACQ-CL A / EPHY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EPIPHANY TECHNOLOGY ACQ-CL A?

ChartMill assigns a fundamental rating of 1 / 10 to EPHY.


What is the valuation status for EPHY stock?

ChartMill assigns a valuation rating of 1 / 10 to EPIPHANY TECHNOLOGY ACQ-CL A (EPHY). This can be considered as Overvalued.


How profitable is EPIPHANY TECHNOLOGY ACQ-CL A (EPHY) stock?

EPIPHANY TECHNOLOGY ACQ-CL A (EPHY) has a profitability rating of 1 / 10.


What are the PE and PB ratios of EPIPHANY TECHNOLOGY ACQ-CL A (EPHY) stock?

The Price/Earnings (PE) ratio for EPIPHANY TECHNOLOGY ACQ-CL A (EPHY) is 43.89 and the Price/Book (PB) ratio is 1.33.